Uterine Mass Found in a 52-Year-Old Woman

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS

May 1st 2025

Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Efti plus pembrolizumab demonstrated no new safety signals in the TACTI-003 trial.

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Related Content

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS

May 1st 2025

Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.